Accessible healthcare

Accessible healthcare

As one of the leading generic manufacturers, we deliver on the objective, which is to produce high-quality, state-of-the-art and affordable generic medicines for the most common diseases of our time.

Patient tailored product portfolio

Our product portfolio – more than half of which consists of cardiovascular medicines – follows the guidelines of the 2030 Agenda for Sustainable Development laid down by United Nations. Physicians can choose from many generic medicines that combine several active ingredients and prescribe the most suitable therapy for each patient for the best treatment outcome.

Affordable medicines

As one of the leading generic manufacturers, we deliver on our objective, which is to produce high-quality, state-of-the-art and affordable medicines for the most common diseases of our time. Our medicines add up to great savings for patients and public health care budgets, making us an important partner of national healthcare systems and patients.

R&D and innovative culture

Our continuous investments into knowledge and state-of-the-art equipment are key to maintaining our competitive edge over generic producers. We extend our key therapeutic areas by constantly developing and obtaining marketing authorisations for new products. We introduce state-of-the-art technologies to ensure undisturbed supply, highest quality and affordable products. We develop innovative products in complex pharmaceutical forms with added value for patients.

Efficient registration procedures

Efficient development process and registration procedures provide us with a competitive advantage. These allow us to offer high-quality, safe and effective medicines to patients soon after patent protection expiry and all the marketing authorisations have been obtained.

Expert support for health professionals

Healthcare professionals are an important link between us and patients – we provide them with the latest, clear, accurate and balanced information on therapeutic ares, therapies and our products, so that they can make the best possible decision regarding therapy for their patients.

Awareness of healthy lifestyles and identification of widespread diseases

Our mission is living a healthy life; to implement it we carry out many activities for our employees and the lay public that highlight the problems related to healthcare and the importance of risk factor identification for individual chronic diseases, particularly cardiovascular and mental diseases, and promote activities that contribute to a healthy lifestyle.

Uninterrupted supply of medicines

We base the principles of our social responsibility on providing undisturbed supply; this helps us maintain the reputation of being a reliable partner in the eyes of patients and direct customers.

Goals

Introduce key medicines from antidiabetic, antiaggregant, anticoagulant and oncology product groups.
Enter new markets.
Support healthcare professionals in gaining extensive information about diagnostics and treatment of common non-communicable chronic diseases through personal contacts and seminars and modern digital channels.
Develop basic therapies, non-established active ingredients, and new approaches to treatment in selected segments of key therapeutic areas of prescription pharmaceuticals (single-pill combinations).
Develop mobile applications and other digital treatment solutions in select therapeutic areas where we are present with our products.
Develop mobile applications and other digital solutions that assist rapid disease detection and effective treatment, and promote a healthy way of life.
Enable access to affordable, high-quality, safe, efficacious and value-added medicines as one of the leading generic manufacturers and an important partner of local healthcare systems and patients, and generate savings for healthcare systems and end users.
Maintain the high level of innovation resulting in patent applications.
Introduce latest technologies and make improvements constantly, and promote innovation in all areas to ensure uninterrupted availability of products, their top quality, and competitive prices.
Ensure continuous improvement of the quality system and hence the integrated management system through the inventive work in all areas, and generate savings by useful proposals and improvements.
Take the latest scientific findings and new regulatory requirements for APIs and finished products into consideration when drawing up registration documents and registration strategies, and managing product registration procedures.
Maintain high quality registration documents and flexible registration procedures.

OBJECTIVES BY 2026

Average sales volume increase (per year): 5%

Increase the number of patients who take Krka’s cardiovascular agents (direct contribution to the SDG goal from the 2030 Agenda for Sustainable Development): Average 5% annual growth – 33 million patients

Remain one of the leading medicine suppliers on traditional markets in key therapeutic areas, for example cardiovascular diseases (hypertension, hyperlipidemia)

Increase the proportion of sales generated by the Region Overseas Markets in total Krka Group sales

Ensure continuous availability of medicines and monitor satisfaction of direct customers by the CSI index: > 80%

R&D expenses from revenue: < 10.0%

Krka around the world